Related Experiment Video

Updated: May 13, 2026

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Malignant glioma drug discovery - targeting protein kinases

Sith Sathornsumetee1, Kaitlyn A Vredenburgh, Kathryn P Lattimore

  • 1The Preston Robert Tisch Brain Tumour Center, Divisions of Neurology and Neurosurgery, Duke University Medical Center, DUMC 3624, Durham, NC 27710, USA.

Expert Opinion on Drug Discovery
|March 19, 2013
PubMed

Insights

Targeting protein kinases in malignant gliomas shows promise. Novel strategies like multi-targeted inhibitors and biomarker identification are key to overcoming treatment resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Malignant gliomas are aggressive brain tumors with poor prognosis.
  • Current treatments (surgery, radiation, chemotherapy) have limitations.
  • Aberrant protein kinase signaling drives glioma pathogenesis.

Purpose of the Study:

  • To review the role of protein kinases in malignant gliomas.
  • To discuss novel therapeutic strategies targeting these kinases.
  • To highlight the importance of biomarkers for personalized treatment.

Main Methods:

  • Literature review of protein kinases in glioma.
  • Analysis of targeted therapies (monoclonal antibodies, small-molecule inhibitors).
  • Discussion of resistance mechanisms and combination strategies.

Main Results:

  • Protein kinases are frequently dysregulated in malignant gliomas.
  • Targeted therapies show limited efficacy as monotherapies in unselected patients.
  • Resistance mechanisms necessitate novel therapeutic approaches.

Conclusions:

  • Targeting aberrant protein kinases is a promising therapeutic avenue for malignant gliomas.
  • Combination therapies and multi-targeted inhibitors may enhance efficacy.
  • Biomarker identification is crucial for patient selection and treatment success.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...